Chiaretti S et al. Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed Ph+ acute lymphoblastic leukemia patients. Preliminary results of the Gimema ALLL2820 trial. ASH 2023;Abstract 4249.

Foa R et al. Long-term results of the frontline dasatinib/blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for adult Ph+ acutelymphoblastic leukemia. ASH 2023;Abstract 4250.

Gong X et al. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. ASH 2023;Abstract 827.

Haddad FG et al. Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia: Updates from a phase II trial. ASH 2023;Abstract 2827.

Jabbour E et al. Treatment of adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—From intensive chemotherapy combinations to chemotherapy-free regimens. JAMA Oncol 2024;8(9):1340-48. Abstract

Jabbour E et al. First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). ASCO 2023;Abstract 398868.

Jabbour E et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: A US, single-centre, single-arm, phase 2 trial. Lancet Haematol 2023;10(1):e24-34. Abstract

Kantarjian H et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 2023;98(3):493-501. Abstract

Luskin MR et al. A phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for BCR-ABL1-positive ALL and blast phase CML in adults. ASH 2023;Abstract 965.

Paul S et al. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol 2023;98(1):E11-4. Abstract

Short NJ et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 2023;98(8):1196-203. Abstract

Zhang M et al. Dasatinib and CAR-T cell therapy for newly diagnosed Ph-positive acute lymphoblastic leukemia in adults. ASH 2023;Abstract 891.